No information is available on the clinical use of vismodegib during breastfeeding. Because vismodegib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is 4 days and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during vismodegib therapy and for 24 months after the final dose.
关于维莫德吉在哺乳期的临床应用尚无可用信息。由于维莫德吉与血浆蛋白的结合率超过99%，其在乳汁中的含量可能较低。然而，其半衰期为4天，可能会在婴儿体内蓄积。制造商建议在维莫德吉治疗期间及最后一剂后24个月内停止母乳喂养。
